A team of scientists from the Biochemical Sciences Division, CSIR-National Chemical Laboratory, India Academy of Scientific and Innovative Research (AcSIR), Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, and INTOX Private Limited, Pune, worked on the efficacy of drug repurposing for treating C-19.
To read more articles on Remdesivir, click here
“Our analysis suggested Sofosbuvir in combination with Ledipasvir and Daclatasvir as potential therapeutic agents for C-19. The combined score suggests that these combinations have superior anti-SARS-CoV-2 potential than Remdesivir and other investigational drugs,” they said in a paper published in Current Science.
They said the present work provides a rationale-based approach to select drugs with possible anti-C-19 activity for further clinical evaluation.
With the shortage of Remdesivir, the combination can be used to save the lives of severe C-19 patients.
“Drug repurposing has been utilised as the most preferred therapeutic intervention for C-19 mitigation due to its necessity and feasibility. To prioritise therapeutic regime against C-19, we used 61 antiviral drugs and their combinations,” said the paper.
The team said the findings provide a scientific rationale for applying Ledipasvir and Daclatasvir in combination with Sofosbuvir for C-19 management.
Subscribe for daily free updates on Telegram
For daily free updates on WhatsApp, click here